Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children, Growth Hormone Deficiency, Pediatric
- Main trialPhase 3
- “This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children. It aims to determine whether the annual height velocity (an index of height growth rate) in children diagnosed with GHD after 52 weeks of GB06 intervention is comparable to that of Norditropin®FlexProTM. To achieve this, the participants will administer GB06 or Norditropin®FlexProTM at 0.035mg/kg/day for 52 consecutive weeks.”In the company’s words, NCT07553351 on ClinicalTrials.gov
Other drugs for Growth Hormone Deficiency (GHD)
- LUM-201Lumos Pharma · Phase 3
- InpegsomatropinXiamen Amoytop Biotech Co., Ltd. · Phase 2
- GenSci134Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
- Recombinant Human Growth HormoneChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
Coming up1
- 25 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 25 Jul 2028 | GB06 Phase III Trial for Pediatric Growth Hormone Deficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026